Cofactor Genomics
Cofactor closes the precision medicine gap with predictive diagnostics
What they do
Clinicians lack accurate biomarkers to predict which patients will respond to therapies, especially immunotherapy, leading to suboptimal treatment decisions and outcomes.
The company provides predictive diagnostics using RNA data and predictive immune modeling to generate better biomarkers for treatment response prediction.
Oncologists and clinical labs at hospitals and healthcare systems that need diagnostic tests to guide patient treatment decisions.
Founders
Dr. Dave Messina has over 25 years of experience in healthcare and has been leading healthcare investments at Pioneer Fund since 2019. He has led 100+ deals including top portfolio companies like Gilgamesh ($1B exit to Abbvie) and Assort Health ($500M+ valuation). Previously he founded the RNA and machine learning company Cofactor Genomics (YC S15) and led it to national Medicare reimbursement. Dr. Messina also worked on the Human Genome Project.
Company timeline
- Founded2015
- YC batchSummer 2015
- StatusActive
- Team size13 people
- LocationSt. Louis, MO, USA
Similar startups
